40

DOCKET NO.: WYNC-0774/AM100978

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Albert John Molinari et al.

Confirmation No.: 9854

Application No.: 10/718,461

Group Art Unit: 1632

Filing Date: November 20, 2003

Examiner: Not yet assigned

Substituted Dihydrophenanthridinesulfonamides

DATE OF DEPOSIT: July 15, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

TYPED NAME: Heather Kite

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

 \boxtimes In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required. In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore: Certification in Accordance with § 1.97(e) is attached; or The fee of \$180.00 as set forth in \$1.17(p) is attached. In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in \S 1.17(p). Copies of each of the references listed on the attached Form PTO-1449 are П enclosed herewith. \boxtimes Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT: \boxtimes A Copy of reference 63 listed on the attached Form PTO 1449 is not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).

DOCKET NO.: WYNC-0774/AM100978-3-

PATENT

M	in view of the voluminous nature of references 61 and 62, and the
	likelihood that these references are available to the Examiner, copies
	are not enclosed herewith.
	In accordance with § 1.98(d), copies of the following references listed
	on the attached Form PTO-1449 are not enclosed herewith because
	they were previously cited by or submitted to the U.S. Patent and
	Trademark Office in patent application(s) for which a claim for priority
	under 35 U.S.C.§ 120 have been made in the instant application:

Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No.

, filed

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: Jun/ 14,2004

Joseph Lucci Registration No. 33,307

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439



List of Paten Cited b (Use several s U.S. Departn	-1449 Modified t and Publications by Applicant cheets if necessary) nent of Commerce Trademark Office	Docket No. WYNC-0774/ AM100978 Applicant Albert John Molinari et Filing Date November 20, 2003 Confirmation No. 9854	Application No. 10/718,461 al. Group 1632	
OTHEI	R DOCUMENTS (Includ	ling Author, Title, Date,	Pertinent Pages, Etc.)	
 Adams, M. R. et al., "Inhibition of Coronary Artery Atherosclerosis by 17-beta Estradiol in Ovariectomized Monkeys," Arterio., 1990, 10(6),1051-1057 Alexander et. al., "Initiation of Hormone Replacement Therapy After Acute Myocardial Infarction Is Associated With More Cardiac Events During Follow-U J. Am. Coll. Cardio., 2001, 38, 1-7 Bauer M. A., Herrmann F., "Interleukin-6 in clinical medicine," Ann. Hematol., 1991, 62, 203-210 Cefalu, W., "The Use of Hormone Replacement Therapy in Postmenopausal Worwith Type 2 Diabetes," J Womens Health & Gender-based Med., 2001, 10(3), 24 255 Chin-Chi Lin et.al., "Pulmonary function changes and increased Th-2 cytokine expression and nuclear factor kB activation in the lung after sensitization and allergen challenge in brown Norway rats," Immunol. Lett., 2000, 73, 57-64 Delyani, J. A. et al., "Protection from Myocardial Reperfusion Injury by Acute Administration of 17 β-Estradiol," J. Molec. Cell. Cardiol., 1996, 28, 1001-1008 Felson, D. T. et al., "The effects of estrogen on osteoarthritis,", Curr Opinion Rhe 				
9	 Chem. Soc., 1950, 72, 3282-3 Grigg, R. et al., "Palladium Catalysed Triscyclisation-Anion Capture Queuing Cascades," Tetrahedron Lett., 1997, 38(10), 1825-1828 			
EXAMINER DATE CONSIDERED				

Form PTO-	Docket No. WYNC-077 AM100978	74/	Application No. 10/718,461	
List of Patent and Cited by (Use several sh	Applicant Albert John Molinari et al.			
_	U.S. Department of Commerce Patent and Trademark Office			Group 1632
		Confirmation 9854	on No.	
OTHER	DOCUMENTS (Includ	ing Author,	Title, Date, l	Pertinent Pages, Etc.)
	Halides and Related Tand 3862	dem Cyclisat	ions," <i>Tetrah</i>	ar Coupling of Aryl and Benzylic edron Lett., 1991, 32(31), 3859-
	Hormone Therapy and Pr Med., 2000 , 133, 933-41	rimary Preve	ntion of Card	Study of Postmenopausal iovascular Disease," Ann. Int.
	 Hulley, S. et. al., "Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women," J. Am. Med. Assoc., 1998, 280, 605-13 Huppatz, J. L. et al., "Pschorr Reactions With Sulphonamides Derived From N-Benzyl- o-Phenylenediamine: A New Route to Phenanthridine, and a New Type of Molecular Rearrangement," Aust. J. Chem., 1963, 16, 417-431 Huppatz, J. L. et al., "Synthesis of 9-Bromophenanthridine and 7-Bromophenanthridine by Pschorr Reactions with Sulphonamides Derived from N-Bromobenzyl- and N-o-Bromobenzyl-o-Phenylenediamines, and a New Route to N-Sulphonylcarbazoles," Aust. J. Chem., 1964, 17, 1407-1417 Huppatz, J. L. et al., "Pschorr Reactions with Sulphonamides Derived from N-Aminobenzyl-Aniline: Synthesis of 4-Bromophenanthridine and Formation of 6-Phenyl-7H-Dibenzo[d,f]-[1,2]-Thiazepine-5-Dioxide," Aust. J. Chem., 1965, 18(2), 206-212 			
16				
	Compound," J. Heterocycl. Chem., Mar-Apr 1984, 21, 425-427			, 21, 425-427
				hem. Molec. Biol., 1997, 60, 11-17
	sulfonamides or Benzoic	and Naphtho	oic Acids with	2'-Phenylphenyl)benzene- n Alkenes Using a Palladium- , 1998 , <i>63</i> ,(15), 5211-5215
EXAMINER			DATE CON	SIDERED

Cited by Applicant (Use several sheets if necessary)			-1449 Modified	Docket No. WYNC-0774/ AM100978	Application No. 10/718,461	
Patent and Trademark Office Plant Date November 20, 2003 1632				1		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) 21 Nathan, L. et. al., "Estradiol Inhibits Leukocyte Adhesion and Transendothelial Migration in Rabbits In Vivo," Circ. Res., 1999, 85, 377-385 22 Paterson et al., "Azabenzocycloheptenones. Part IV. An Azadibenzotropone," J. Chem. Soc., 1962, 3468-3472 23 Patra, P. K., et al., "A New Regiospecific Method for the Synthesis of Substituted Phenanthridines and Benzo[j]phenanthridines via Aromatic Annelation of 1-N-Benzenesulfonyl-3-[Bis9methylthio)methylene]-1,2,3,4-tetrahydroquinoline-4-one," Tetrahedron, 1998, 54(34), 10167-10178 24 Peaston, W. C. et al, "Azabenzocycloheptenones. VIII. Further observations in the dibenz[b,d]azepin-7-one field," J. Chem. Soc., 1968, 19, 2481-4. Chemical Abstract Service, HCAPLUS Accession No. 1968:496433, Document No. 69:96433 (Abstract) 25 Pelletier et al., "Osteoarthritis, an Inflammatory Disease," Arthr. & Rheum., 2001, 44:1237-1247 26 Reis et. al., "Estrogen Is Associated With Improved Survival in Aging Women With Congestive Heart Failure: Analysis of the Vesnarinone Studies," J. Am. Coll. Cardio., 2000, 36, 529-33 27 Roth, A. et. al., "Phytoestrogen Kaempferol (3,4',5,7-Tetrahydroxylflavone) Protec PC12 and T47D Cells From β-Amyloid-Induced Toxicity," J. Neurosci. Res., 1999, 57, 399-404 28 Schonknecht, P. et. al., "Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease," Neurosci. Lett., 2001, 307, 122-124 29 Sullivan, T. R. et al. "Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model," J. Clin. Invst., 1995, 96, 2482-8 30 Ulmer, L. et al., "Mono- and bisfunctionalization of fullerenes with N-containing reactants," J. Inf. Rec., 1998, 24(3-4), 243-247. Chemical Abstracts Service, Accession No. 1999:251961, HCAPLUS Registry No. 226909-66-6 (Abstract)					1 -	
 Nathan, L. et. al., "Estradiol Inhibits Leukocyte Adhesion and Transendothelial Migration in Rabbits In Vivo," Circ. Res., 1999, 85, 377-385 Paterson et al., "Azabenzocycloheptenones. Part IV. An Azadibenzotropone," J. Chem. Soc., 1962, 3468-3472 Patra, P. K., et al., "A New Regiospecific Method for the Synthesis of Substituted Phenanthridines and Benzo[j]phenanthridines via Aromatic Annelation of 1-N-Benzenesulfonyl-3-[Bis9methylthio)methylene]-1,2,3,4-tetrahydroquinoline-4-one, Tetrahedron, 1998, 54(34), 10167-10178 Peaston, W. C. et al, "Azabenzocycloheptenones. VIII. Further observations in the dibenz[b,d]azepin-7-one field," J. Chem. Soc., 1968, 19, 2481-4. Chemical Abstraction Service, HCAPLUS Accession No. 1968:496433, Document No. 69:96433 (Abstract) Pelletier et al., "Osteoarthritis, an Inflammatory Disease," Arthr. & Rheum., 2001, 44:1237-1247 Reis et. al., "Estrogen Is Associated With Improved Survival in Aging Women With Congestive Heart Failure: Analysis of the Vesnarinone Studies," J. Am. Coll. Cardio., 2000, 36, 529-33 Roth, A. et. al., "Phytoestrogen Kaempferol (3,4',5,7-Tetrahydroxylflavone) Protectory and T47D Cells From β-Amyloid-Induced Toxicity," J. Neurosci. Res., 1999, 57, 399-404 Schonknecht, P. et. al., "Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease," Neurosci. Lett., 2001, 307, 122-124 Sullivan, T. R. et al. "Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model," J. Clin. Invst., 1995, 96, 2482-8 Ulmer, L. et al., "Mono- and bisfunctionalization of fullerenes with N-containing reactants," J. Inf. Rec., 1998, 24(3-4), 243-247. Chemical Abstracts Service, Accession No. 1999:251961, HCAPLUS Registry No. 226909-66-6 (Abstract) 						
 Migration in Rabbits In Vivo," Circ. Res., 1999, 85, 377-385 22 Paterson et al., "Azabenzocycloheptenones. Part IV. An Azadibenzotropone," J. Chem. Soc., 1962, 3468-3472 23 Patra, P. K., et al., "A New Regiospecific Method for the Synthesis of Substituted Phenanthridines and Benzo[j]phenanthridines via Aromatic Annelation of 1-N-Benzenesulfonyl-3-[Bis9methylthio)methylene]-1,2,3,4-tetrahydroquinoline-4-one," Tetrahedron, 1998, 54(34), 10167-10178 24 Peaston, W. C. et al, "Azabenzocycloheptenones. VIII. Further observations in the dibenz[b,d]azepin-7-one field," J. Chem. Soc., 1968, 19, 2481-4. Chemical Abstract Service, HCAPLUS Accession No. 1968:496433, Document No. 69:96433 (Abstract) 25 Pelletier et al., "Osteoarthritis, an Inflammatory Disease," Arthr. & Rheum., 2001, 44:1237-1247 26 Reis et. al., "Estrogen Is Associated With Improved Survival in Aging Women With Congestive Heart Failure: Analysis of the Vesnarinone Studies," J. Am. Coll. Cardio., 2000, 36, 529-33 27 Roth, A. et. al., "Phytoestrogen Kaempferol (3,4',5,7-Tetrahydroxylflavone) Protect PC12 and T47D Cells From β-Amyloid-Induced Toxicity," J. Neurosci. Res., 1999, 57, 399-404 28 Schonknecht, P. et. al., "Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease," Neurosci. Lett., 2001, 307, 122-124 29 Sullivan, T. R. et al. "Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model," J. Clin. Invst., 1995, 96, 2482-8 30 Ulmer, L. et al., "Mono- and bisfunctionalization of fullerenes with N-containing reactants," J. Inf. Rec., 1998, 24(3-4), 243-247. Chemical Abstracts Service, Accession No. 1999:251961, HCAPLUS Registry No. 226909-66-6 (Abstract) 	OT	THE	R DOCUMENTS (Includ	ing Author, Title, D	ate, Pertinent Pages, Etc.)	
 Paterson et al., "Azabenzocycloheptenones. Part IV. An Azadibenzotropone," J. Chem. Soc., 1962, 3468-3472 Patra, P. K., et al., "A New Regiospecific Method for the Synthesis of Substituted Phenanthridines and Benzo[j]phenanthridines via Aromatic Annelation of 1-N-Benzenesulfonyl-3-[Bis9methylthio)methylene]-1,2,3,4-tetrahydroquinoline-4-one, Tetrahedron, 1998, 54(34), 10167-10178 Peaston, W. C. et al, "Azabenzocycloheptenones. VIII. Further observations in the dibenz[b,d]azepin-7-one field," J. Chem. Soc., 1968, 19, 2481-4. Chemical Abstract Service, HCAPLUS Accession No. 1968:496433, Document No. 69:96433 (Abstract) Pelletier et al., "Osteoarthritis, an Inflammatory Disease," Arthr. & Rheum., 2001, 44:1237-1247 Reis et. al., "Estrogen Is Associated With Improved Survival in Aging Women With Congestive Heart Failure: Analysis of the Vesnarinone Studies," J. Am. Coll. Cardio., 2000, 36, 529-33 Roth, A. et. al., "Phytoestrogen Kaempferol (3,4',5,7-Tetrahydroxylflavone) Protect PC12 and T47D Cells From β-Amyloid-Induced Toxicity," J. Neurosci. Res., 1999 57, 399-404 Schonknecht, P. et. al., "Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease," Neurosci. Lett., 2001, 307, 122-124 Sullivan, T. R. et al. "Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model," J. Clin. Invst., 1995, 96, 2482-8 Ulmer, L. et al., "Mono- and bisfunctionalization of fullerenes with N-containing reactants," J. Inf. Rec., 1998, 24(3-4), 243-247. Chemical Abstracts Service, Accession No. 1999:251961, HCAPLUS Registry No. 226909-66-6 (Abstract) 		21				
 Phenanthridines and Benzo[j]phenanthridines via Aromatic Annelation of 1-N-Benzenesulfonyl-3-[Bis9methylthio)methylene]-1,2,3,4-tetrahydroquinoline-4-one, Tetrahedron, 1998, 54(34), 10167-10178 24 Peaston, W. C. et al, "Azabenzocycloheptenones. VIII. Further observations in the dibenz[b,d]azepin-7-one field," J. Chem. Soc., 1968, 19, 2481-4. Chemical Abstract Service, HCAPLUS Accession No. 1968:496433, Document No. 69:96433 (Abstract) 25 Pelletier et al., "Osteoarthritis, an Inflammatory Disease," Arthr. & Rheum., 2001, 44:1237-1247 26 Reis et. al., "Estrogen Is Associated With Improved Survival in Aging Women With Congestive Heart Failure: Analysis of the Vesnarinone Studies," J. Am. Coll. Cardio., 2000, 36, 529-33 27 Roth, A. et. al., "Phytoestrogen Kaempferol (3,4',5,7-Tetrahydroxylflavone) Protect PC12 and T47D Cells From β-Amyloid-Induced Toxicity," J. Neurosci. Res., 1999 57, 399-404 28 Schonknecht, P. et. al., "Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease," Neurosci. Lett., 2001, 307, 122-124 29 Sullivan, T. R. et al. "Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model," J. Clin. Invst., 1995, 96, 2482-8 30 Ulmer, L. et al., "Mono- and bisfunctionalization of fullerenes with N-containing reactants," J. Inf. Rec., 1998, 24(3-4), 243-247. Chemical Abstracts Service, Accession No. 1999:251961, HCAPLUS Registry No. 226909-66-6 (Abstract) 		22	Paterson et al., "Azabenz Chem. Soc., 1962, 3468-	cocycloheptenones. Pa 3472	art IV. An Azadibenzotropone," J.	
 Peaston, W. C. et al, "Azabenzocycloheptenones. VIII. Further observations in the dibenz[b,d]azepin-7-one field," J. Chem. Soc., 1968, 19, 2481-4. Chemical Abstract Service, HCAPLUS Accession No. 1968:496433, Document No. 69:96433 (Abstract) Pelletier et al., "Osteoarthritis, an Inflammatory Disease," Arthr. & Rheum., 2001, 44:1237-1247 Reis et. al., "Estrogen Is Associated With Improved Survival in Aging Women With Congestive Heart Failure: Analysis of the Vesnarinone Studies," J. Am. Coll. Cardio., 2000, 36, 529-33 Roth, A. et. al., "Phytoestrogen Kaempferol (3,4',5,7-Tetrahydroxylflavone) Protect PC12 and T47D Cells From β-Amyloid-Induced Toxicity," J. Neurosci. Res., 1999 57, 399-404 Schonknecht, P. et. al., "Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease," Neurosci. Lett., 2001, 307, 122-124 Sullivan, T. R. et al. "Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model," J. Clin. Invst., 1995, 96, 2482-8 Ulmer, L. et al., "Mono- and bisfunctionalization of fullerenes with N-containing reactants," J. Inf. Rec., 1998, 24(3-4), 243-247. Chemical Abstracts Service, Accession No. 1999:251961, HCAPLUS Registry No. 226909-66-6 (Abstract) 		23	 Patra, P. K., et al., "A New Regiospecific Method for the Synthesis of Substituted Phenanthridines and Benzo[j]phenanthridines via Aromatic Annelation of 1-N-Benzenesulfonyl-3-[Bis9methylthio)methylene]-1,2,3,4-tetrahydroquinoline-4-one," Tetrahedron, 1998, 54(34), 10167-10178 Peaston, W. C. et al, "Azabenzocycloheptenones. VIII. Further observations in the dibenz[b,d]azepin-7-one field," J. Chem. Soc., 1968, 19, 2481-4. Chemical Abstracts Service, HCAPLUS Accession No. 1968:496433, Document No. 69:96433 			
 Pelletier et al., "Osteoarthritis, an Inflammatory Disease," Arthr. & Rheum., 2001, 44:1237-1247 Reis et. al., "Estrogen Is Associated With Improved Survival in Aging Women With Congestive Heart Failure: Analysis of the Vesnarinone Studies," J. Am. Coll. Cardio., 2000, 36, 529-33 Roth, A. et. al., "Phytoestrogen Kaempferol (3,4',5,7-Tetrahydroxylflavone) Protect PC12 and T47D Cells From β-Amyloid-Induced Toxicity," J. Neurosci. Res., 1999 57, 399-404 Schonknecht, P. et. al., "Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease," Neurosci. Lett., 2001, 307, 122-124 Sullivan, T. R. et al. "Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model," J. Clin. Invst., 1995, 96, 2482-8 Ulmer, L. et al., "Mono- and bisfunctionalization of fullerenes with N-containing reactants," J. Inf. Rec., 1998, 24(3-4), 243-247. Chemical Abstracts Service, Accession No. 1999:251961, HCAPLUS Registry No. 226909-66-6 (Abstract) 		24				
 Congestive Heart Failure: Analysis of the Vesnarinone Studies," J. Am. Coll. Cardio., 2000, 36, 529-33 27 Roth, A. et. al., "Phytoestrogen Kaempferol (3,4',5,7-Tetrahydroxylflavone) Protect PC12 and T47D Cells From β-Amyloid-Induced Toxicity," J. Neurosci. Res., 1999 57, 399-404 28 Schonknecht, P. et. al., "Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease," Neurosci. Lett., 2001, 307, 122-124 29 Sullivan, T. R. et al. "Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model," J. Clin. Invst., 1995, 96, 2482-8 30 Ulmer, L. et al., "Mono- and bisfunctionalization of fullerenes with N-containing reactants," J. Inf. Rec., 1998, 24(3-4), 243-247. Chemical Abstracts Service, Accession No. 1999:251961, HCAPLUS Registry No. 226909-66-6 (Abstract) 		25	Pelletier et al., "Osteoarthritis, an Inflammatory Disease," Arthr. & Rheum., 2001,			
 Roth, A. et. al., "Phytoestrogen Kaempferol (3,4',5,7-Tetrahydroxylflavone) Protect PC12 and T47D Cells From β-Amyloid-Induced Toxicity," J. Neurosci. Res., 1999 57, 399-404 Schonknecht, P. et. al., "Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease," Neurosci. Lett., 2001, 307, 122-124 Sullivan, T. R. et al. "Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model," J. Clin. Invst., 1995, 96, 2482-8 Ulmer, L. et al., "Mono- and bisfunctionalization of fullerenes with N-containing reactants," J. Inf. Rec., 1998, 24(3-4), 243-247. Chemical Abstracts Service, Accession No. 1999:251961, HCAPLUS Registry No. 226909-66-6 (Abstract) 		26	Congestive Heart Failure	e: Analysis of the Ves		
 Schonknecht, P. et. al., "Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease," Neurosci. Lett., 2001, 307, 122-124 Sullivan, T. R. et al. "Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model," J. Clin. Invst., 1995, 96, 2482-8 Ulmer, L. et al., "Mono- and bisfunctionalization of fullerenes with N-containing reactants," J. Inf. Rec., 1998, 24(3-4), 243-247. Chemical Abstracts Service, Accession No. 1999:251961, HCAPLUS Registry No. 226909-66-6 (Abstract) 		 Roth, A. et. al., "Phytoestrogen Kaempferol (3,4',5,7-Tetrahydroxylflavone) Prote PC12 and T47D Cells From β-Amyloid-Induced Toxicity," J. Neurosci. Res., 199 57, 399-404 Schonknecht, P. et. al., "Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease," 				
 Sullivan, T. R. et al. "Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model," J. Clin. Invst., 1995, 96, 2482-8 Ulmer, L. et al., "Mono- and bisfunctionalization of fullerenes with N-containing reactants," J. Inf. Rec., 1998, 24(3-4), 243-247. Chemical Abstracts Service, Accession No. 1999:251961, HCAPLUS Registry No. 226909-66-6 (Abstract) 						
reactants," J. Inf. Rec., 1998, 24(3-4), 243-247. Chemical Abstracts Service, Accession No. 1999:251961, HCAPLUS Registry No. 226909-66-6 (Abstract)		Sullivan, T. R. et al. "Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model," J. Clin. Invst., 1995, 96, 2482-8			2-8	
		reactants," J. Inf. Rec., 1998, 24(3-4), 243-247. Chemical Abstracts Service,				
31 Yuan et al., "Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of <i>Ikk</i> β," <i>Science</i> , 2001, 293, 1673-7		31	Yuan et al., "Reversal of	Obesity- and Diet-In	duced Insulin Resistance with	
EXAMINER DATE CONSIDERED	EXAMINER		Sameylates of Targeted I			

EXAMINER		DATE C	ONSIDERED	
48	Chemical Abstracts Ser	vice, CA Registry No. 2	279680-74-9	
47	Chemical Abstracts Ser	vice, CA Registry No. 2	279680-75-0	
46	Chemical Abstracts Ser	rice, CA Registry No. 1096-83-9		
45	Chemical Abstracts Serv	vice, CA Registry No. 19711-96-7 vice, CA Registry No. 2608-29-9		
44	Chemical Abstracts Serv			
43	Chemical Abstracts Serv	vice, CA Registry No. 9	91871-03-3	
42	Chemical Abstracts Serv			
41	Chemical Abstracts Serv			
40	Chemical Abstracts Serv	vice, CA Registry No. 2	211621-22-6	
39		vice, CA Registry No. 211621-26-0 vice, CA Registry No. 211621-25-9 vice, CA Registry No. 211621-24-8 vice, CA Registry No. 211621-23-7		
38				
37	Chemical Abstracts Serv			
36	Chemical Abstracts Serv			
35	Chemical Abstracts Serv	vice, CA Registry No. 211621-27-1		
34	Chemical Abstracts Serv	vice, CA Registry No. 2	211621-30-6	
33	Chemical Abstracts Serv	vice, CA Registry No. 2	213486-08-9	
32	Chemical Abstracts Serv	vice, CA Registry No. 2	213486-09-0	
ОТНЕК	R DOCUMENTS (Include	ding Author, Title, Da	te, Pertinent Pages, Etc.)	
		Confirmation No. 9854		
	nent of Commerce rademark Office	Filing Date November 20, 2003	Group 1632	
Cited b	y Applicant heets if necessary)	Applicant Albert John Molinari et al.		
	-1449 Modified t and Publications	Docket No. WYNC-0774/ AM100978	Application No. 10/718,461	

	0-1449 Modified	Docket No. WYNC-0774/ AM100978	Application No. 10/718,461	
Cited	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		et al.	
	ment of Commerce Trademark Office	Filing Date November 20, 2003	Group 1632	
		Confirmation No. 9854		
ОТНЕ	R DOCUMENTS (Inclu	ding Author, Title, Dat	te, Pertinent Pages, Etc.)	
49	Chemical Abstracts Ser	vice, CA Registry No. 2	26909-66-6	
50	Chemical Abstracts Ser	vice, CA Registry No. 2	26909-63-3	
51	Chemical Abstracts Ser	vice, CA Registry No. 2	13486-15-8	
52	Chemical Abstracts Ser	vice, CA Registry No. 2	13486-14-7	
53	Chemical Abstracts Ser	vice, CA Registry No. 2	13486-13-6	
54	Chemical Abstracts Ser	vice, CA Registry No. 2	13486-12-5	
55	Chemical Abstracts Ser	vice, CA Registry No. 2	13486-11-4	
56	Chemical Abstracts Ser	vice, CA Registry No. 2	13486-10-3	
57	Chemical Abstracts Ser	vice, CA Registry No. 2	13486-07-8	
. 58	Chemical Abstracts Ser	vice, CA Registry No. 2	CA Registry No. 213486-05-6	
59	Chemical Abstracts Ser	vice, CA Registry No. 2	13486-04-5	
60	Chemical Abstracts Ser	vice, CA Registry No. 1	88755-32-0	
EXAMINER		DATE CO	ONSIDERED	

List of C (Use sev U.S. De	Paten ited b veral s epartm	-1449 Modified t and Publications by Applicant sheets if necessary) ment of Commerce Trademark Office	Docket No. WYNC-0774/ AM100978 Applicant Albert John Molinari e Filing Date November 20, 2003 Confirmation No. 9854	Application No. 10/718,461 et al. Group 1632
O '.	THE	R DOCUMENTS (Inclu	ding Author, Title, Date	, Pertinent Pages, Etc.)
*	61			nic Chemistry: Reactions, & Sons: New York, 2001
*	62		G. M. Protective Groups	s in Organic Synthesis, 3rd ed.; John
	·			
EXAMINER			DATE CO	NSIDERED

^{*} A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and may be obtainable by the Examiner.

© 2004 ww

Form PTO-1449 Modified				Docket No. WYNC-0774/ AM100978	Application No. 10/718,461	
(Use several sheets if necessary) U.S. Department of Commerce				Applicant Albert John Molinari et al.		
				Filing Date November 20, 2003	Group 1632	
				Confirmation No. 9854		
-		U	. S. PATEN	T DOCUMENTS	•	
Examiner Initial		Document No.	Date	Name	Class	Subclass
	63	5,153,185	10/06/92	DiNinno et al.	514	210.14
		FOR	REIGN PAT	ENT DOCUMENTS		
Examiner Document No. Date				Country	Tra YES	anslation NO
Initial	64	00/42018 A1	07/20/00	wo	1123	NO
	65	00/42020 A1	07/20/00	wo		
	66	01/42219 A2	06/14/01	wo		
	67	02/20463 A1	03/14/02	wo		
	68	5762M	02/05/68	FR		X
	69	1 135 947 A	12/11/68	GB		
	70	761669 A2, A3	03/12/97	EP		
	71	509756 A1	10/21/92	EP		
	72	509780 A1	10/21/92	EP		
EXAMINER			DATE CONSIDER	ED		